2015
DOI: 10.3109/10428194.2014.1001987
|View full text |Cite
|
Sign up to set email alerts
|

High-dose chemotherapy with carmustine, etoposide, cytarabine and melphalan followed by autologous stem cell transplant is an effective treatment for elderly patients with poor-prognosis lymphoma

Abstract: Autologous stem cell transplant (ASCT) after high-dose chemotherapy (HDT) increases overall survival when used in relapsed non-Hodgkin lymphoma (NHL) in patients under 65 years old. Limited experience is available for older patients. We present a retrospective analysis of 73 consecutive patients aged over 65 years treated for aggressive or relapsed lymphoma by HDT with carmustine, etoposide, cytarabine and melphalan (BEAM) at full dosage followed by ASCT. Patient data were obtained from medical charts from two… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

2
9
0

Year Published

2015
2015
2023
2023

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 21 publications
(11 citation statements)
references
References 52 publications
2
9
0
Order By: Relevance
“…We demonstrated a NRM of 2·5% at 1 year, which is comparable to a number of other recent publications reporting outcomes in this age group. Dahi et al () showed a 1‐year TRM of 4% (both NRM and progression were defined as competing risk events); Martin et al () showed a TRM of 2·7% at 100 d, which included death from any cause and Hosing et al () reported a NRM of 12% at 36 months. For patients undergoing ASCT for DLBCL, the European Bone Marrow Tranplant Registry and Japanese Society for Haemopoietic Stem Cell Transplantation Database reported a 1‐year NRM of 8·7% and 5·7% respectively (Jantunen et al , ; Chihara et al , ).…”
Section: Discussionmentioning
confidence: 99%
“…We demonstrated a NRM of 2·5% at 1 year, which is comparable to a number of other recent publications reporting outcomes in this age group. Dahi et al () showed a 1‐year TRM of 4% (both NRM and progression were defined as competing risk events); Martin et al () showed a TRM of 2·7% at 100 d, which included death from any cause and Hosing et al () reported a NRM of 12% at 36 months. For patients undergoing ASCT for DLBCL, the European Bone Marrow Tranplant Registry and Japanese Society for Haemopoietic Stem Cell Transplantation Database reported a 1‐year NRM of 8·7% and 5·7% respectively (Jantunen et al , ; Chihara et al , ).…”
Section: Discussionmentioning
confidence: 99%
“…Patients with ALL were treated with intensive chemotherapy according to HOVON-100 and HOVON-71 study protocols ( Daenen et al , 2012 ). The NHL/HL patients were treated with BEAM and ASCT ( Holmberg and Maloney, 2011 ; Martin et al , 2015 ) and MM patients with high-dose melphalan (100 mg m −2 on days −3 and −2) before ASCT ( Engelhardt et al , 2014 ). BEAM is a combination of carmustine, etoposide, cytarabine and melphalan.…”
Section: Methodsmentioning
confidence: 99%
“…Since ASCT was introduced more than 30 years ago, studies have suggested that outcome might be improved by conditioning with BEAM or BEAC instead of cyclophosphamide-total body irradiation [11] (although recent data are less persuasive [12]), peripheral instead of bone-marrow stem cells [13], and rituximab in pre-ASCT treatments for patients with CD20 + lymphoma [14]. High age has been proposed as a risk-factor for TRM [15]; however, newer data indicate that it is not an independent factor [10, 16, 17].…”
Section: Introductionmentioning
confidence: 99%